GBL to secure a $1.7Bn Affidea deal with Switzerland-based tycoon
Category: #business  | By Nikita Chaurasia  | Date: 2022-04-18 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

GBL to secure a $1.7Bn Affidea deal with Switzerland-based tycoon

Groupe Bruxelles Lambert SA, a Europe based investment company, is on the verge to close a deal to purchase Affidea, a health-care service company from Ernesto Bertarelli, Switzerland’s richest man.

As per credible sources, GBL is nearing to outbid its rival private equity companies and industry players.

Apparently, the deal could value the Netherlands-based firm at almost $1.7 billion (nearly 1.6 million euros).

It has been reported that B-Flexion, previously called as Waypoint Capital, is Geneva-based Bertarelli family’s private investment company and has been working closely with the advisors to study a listing or sale of Affidea.

For the unversed, Affidea offers outpatient cancer care along with diagnostic imaging services, radiation oncology services, and chemotherapy.

Not to mention, GBL has been listed on Brussels stock exchange for almost 60 years and more and has showed a net asset price of 22.5 billion euros in December.

According to reports, the transaction would highlight an increase in the private capital and family-owned investment funds to make deals, particularly focusing on firms that can develop through investments and acquisitions over a long period.

As per claims, Affidea started its functioning three decades ago and presently runs around 319 centers across 15 countries in Europe. Affidea has grown through mergers and acquisitions and is organically serving about 10 million patients each year.

Meanwhile, majority of Bertarelli’s fortune can be traced to $8.6 billion through sale of Serono, a fertility drug producer, to Merck KGaA back in 2006. Most of the assets have been reinvested via B-Flexion which include tech-based venture funds and commercial real estate.

It has been speculated that the discussions between B-Flexion and GBL are at an advanced level but none of the firm’s representatives have provided a firm statement.  

Source Credit: - https://www.bloombergquint.com/business/gbl-said-near-to-1-7-billion-affidea-deal-with-swiss-tycoon

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Fintech firm PayPal to shed around 2000 staff as global economy plummets

Fintech firm PayPal to shed around 2000 staff as global economy plummets

By Nikita Chaurasia

PayPal, the U.S.-based fintech giant, has reportedly announced that it will cut nearly 2000 jobs, approximately 7% of its workforce, as it turns the latest prominent tech company to shed staff in a bid to cut costs. The online payments provider cl...

EasyJet sees a rise in bookings as customers plan their next vacations

EasyJet sees a rise in bookings as customers plan their next vacations

By Nikita Chaurasia

British multinational low-cost airline group, EasyJet, has reported a record surge in bookings for the month of January as people prioritized their travel plans for the coming year. The news comes as airlines world over start to show signs that they&...

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

By Nikita Chaurasia

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the ...